1. Home
  2. PDSB vs RFL Comparison

PDSB vs RFL Comparison

Compare PDSB & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PDS Biotechnology Corporation

PDSB

PDS Biotechnology Corporation

N/A

Current Price

$1.17

Market Cap

62.0M

Sector

Health Care

ML Signal

N/A

Logo Rafael Holdings Inc. Class B

RFL

Rafael Holdings Inc. Class B

N/A

Current Price

$1.40

Market Cap

69.7M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
PDSB
RFL
Founded
2005
2017
Country
United States
United States
Employees
10
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
62.0M
69.7M
IPO Year
2015
2017

Fundamental Metrics

Financial Performance
Metric
PDSB
RFL
Price
$1.17
$1.40
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$9.00
N/A
AVG Volume (30 Days)
1.1M
51.2K
Earning Date
05-14-2026
06-10-2026
Dividend Yield
N/A
N/A
EPS Growth
28.16
28.28
EPS
N/A
N/A
Revenue
N/A
$917,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
43.96
52 Week Low
$0.51
$1.12
52 Week High
$1.90
$3.19

Technical Indicators

Market Signals
Indicator
PDSB
RFL
Relative Strength Index (RSI) 53.33 59.53
Support Level $0.85 $1.28
Resistance Level $1.47 $1.59
Average True Range (ATR) 0.14 0.07
MACD -0.01 0.00
Stochastic Oscillator 35.86 92.86

Price Performance

Historical Comparison
PDSB
RFL

About PDSB PDS Biotechnology Corporation

PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.

About RFL Rafael Holdings Inc. Class B

Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.

Share on Social Networks: